GTx-104 Resubmission Progress
Grace Therapeutics Prepares GTx-104 NDA Resubmission, Addresses FDA Feedback
Key Points
In the Complete Response Letter, the FDA cited specific CMC/non-clinical deficiencies including “additional leachable data time points for commercial product” and “non-clinical product toxicology” items—areas Grace said are addressable without clinical redesign.
Grace said the new patent is U.S. Patent No. 12,414,943 (“Nimodipine Parenteral Administration”), and described an IP stack: five formulation-composition patents (providing protection through 2037) plus the new IV dosing regimen coverage extending protection through 2043.
Grace reiterated that its FDA orphan drug designation would provide “seven years of marketing exclusivity in United States if certain conditions are met upon FDA approval of the NDA.”
The company provided more granular financial figures: net loss was $7.8 million (loss per share of $0.47) versus $9.6 million (loss per share of $0.79) the prior year; and total R&D expenses were $2.4 million versus $9.5 million, reflecting the STRIVE-ON close-out.
Beyond cash runway, Grace disclosed that general and administrative expenses rose to $8.7 million, driven by “legal, due diligence, and pre-commercial planning costs,” and said its $17.0 million cash balance supported “at least 12 months” of liquidity from the March 31, 2026 reporting date.
Grace Therapeutics reported a narrowed net loss of $7.8 million for the fiscal year ended March 31, 2026, down from $9.6 million the prior year, as the company pivots to fight for FDA approval of its lead drug GTx-104 — an IV nimodipine shot at treating a life-threatening type of brain bleed. The FDA rejected the application in April 2026 with a Complete Response Letter, but Grace says the problems are fixable. Stock Titan reported the company has scheduled a Type A meeting with the FDA to map out its resubmission path.
CEO Prashant Kohli said FDA approval of GTx-104 "would represent the first meaningful innovation in the standard of care for these patients in more than 40 years." The drug targets aneurysmal subarachnoid hemorrhage — a stroke caused by a ruptured brain aneurysm — where the current standard, oral nimodipine, has been in use since the 1980s. Goldea Capital noted Grace now holds $17 million in cash, enough to fund at least 12 months of operations.
FDA Rejection Targets Manufacturing, Not Clinical Data
The FDA's Complete Response Letter did not question whether GTx-104 works. Instead, it flagged Chemistry, Manufacturing, and Controls issues — specifically, gaps in leachable data time points for the commercial product, and non-clinical product toxicology items. Grace says neither problem requires redesigning the clinical trials. That distinction matters enormously for the company's timeline and cash burn.
According to GuruFocus, Grace has scheduled a Type A meeting with the FDA — the agency's highest-priority meeting category — to get clarity on exactly what the resubmission must include. If the FDA agrees that existing clinical data from the Phase 3 STRIVE-ON trial is sufficient, Grace could resubmit by late 2026. The STRIVE-ON trial enrolled 102 patients and showed GTx-104 cut clinically significant hypotension from 35% of patients on oral nimodipine to 28%.
Phase 3 Trial Showed Fewer ICU Days and Better Drug Delivery
The STRIVE-ON safety trial built a strong clinical case for GTx-104. Patients on the IV drug had 1.5 fewer ICU days and 5 fewer days on mechanical ventilation on average. That is a major operational advantage in a critical care setting. Oral nimodipine is hard to give to patients who are unconscious or cannot swallow — a common scenario in aSAH.
Dose delivery was also far better. TipRanks highlighted that 54% of GTx-104 patients received at least 95% of their planned dose, versus just 8% on oral capsules. That gap reflects a core weakness of the oral drug: unpredictable absorption leads to missed or interrupted doses. GTx-104 uses a micelle-based formula that dissolves nimodipine for continuous IV infusion, giving doctors tighter control over plasma levels.
Patent Coverage Extends to 2043, Orphan Drug Status Adds Seven Years
Grace has built a layered intellectual property wall around GTx-104. Five formulation patents protect the drug's composition through 2037. U.S. Patent No. 12,414,943, issued in September 2025, covers the specific IV dosing regimen used in the clinical trials and extends protection through 2043. According to Quartr, Grace also holds FDA orphan drug designation, which would give it seven years of U.S. marketing exclusivity upon approval — on top of the patents.
That combination makes GTx-104 a potentially attractive acquisition target. A buyer would get exclusivity until at least 2043, a clean clinical data package, and no generic competition for seven years post-approval. Grace has not disclosed any partnership talks, but analysts note the single-asset focus — after cutting internal funding for GTx-102 and GTx-101 — signals a company positioning itself for either a deal or a standalone approval push.
Cash Runway Is Tight but Expenses Have Fallen Sharply
Grace's finances improved mostly because spending dropped. R&D expenses fell from $9.5 million to $2.4 million after the STRIVE-ON trial closed out. That offset a rise in general and administrative costs, which climbed from $7.2 million to $8.7 million due to legal fees, due diligence, and pre-commercial planning. The result was a loss per share of $0.47, down from $0.79 the prior year.
The $17 million cash balance covers "at least 12 months" from the March 31, 2026 reporting date, Goldea Capital reported. But Grace was direct: more capital will be needed to fund commercialization if approval comes through. The company also disclosed expected impairment charges of roughly $13.5 million in the first quarter of fiscal 2027, tied to writing down the discontinued GTx-101 and GTx-102 programs. Investors are watching the Type A meeting for any signal on timing and cost of the resubmission.
Sentiment
Mostly PositivePublishers
12
Articles
13
Reach
25
